Guilherme Harada

660 total citations
40 papers, 317 citations indexed

About

Guilherme Harada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Guilherme Harada has authored 40 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 10 papers in Surgery. Recurrent topics in Guilherme Harada's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Guilherme Harada is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). Guilherme Harada collaborates with scholars based in Brazil, United States and Argentina. Guilherme Harada's co-authors include Alexander Drilon, Soo‐Ryum Yang, Emiliano Cocco, Fernando C. Santini, Clare Wilhelm, Christina J. Falcon, Dazhi Liu, Moacyr Roberto Cucê Nobre, Artur Katz and W. Marston Linehan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Guilherme Harada

34 papers receiving 315 citations

Peers

Countries citing papers authored by Guilherme Harada

Since Specialization

Citations

This map shows the geographic impact of Guilherme Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guilherme Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guilherme Harada more than expected).

Fields of papers citing papers by Guilherme Harada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guilherme Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guilherme Harada. The network helps show where Guilherme Harada may publish in the future.

Co-authorship network of co-authors of Guilherme Harada

This figure shows the co-authorship network connecting the top 25 collaborators of Guilherme Harada. A scholar is included among the top collaborators of Guilherme Harada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guilherme Harada. Guilherme Harada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292) 2025 ·JTO Clinical and Research Reports ·Rachel Reingold, (unknown), Guilherme Harada, Andrea P. Moy, George Dranitsaris, Jasmine H. Francis, (unknown), Jenny Lester, (unknown), Dazhi Liu, Mario E. Lacouture, Alexander Drilon	1
2	Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response 2025 ·Critical Reviews in Oncology/Hematology ·(unknown), Mariana de Pauli Paglioni, Ana Gabriela Costa Normando, Aline Lauda Freitas Chaves, Luiz Paulo Kowalski, Gilberto de Castro, (unknown), (unknown), Thiago Bueno de Oliveira, Pedro De Marchi, Guilherme Harada, Milena Perez Mak, Carmen Sílvia Passos Lima, Gustavo Arruda Viani, Fábio Ynoe de Moraes, (unknown), Alan Roger Santos‐Silva, Gustavo A. Nader	2
3	TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers 2024 ·npj Precision Oncology ·Rajat Thawani, Matteo Repetto, Clare Keddy, (unknown), Kristen L. Jones, Kevin D. Nusser, (unknown), Guilherme Harada, Alexander Drilon, Monika A. Davare	5
4	Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma 2024 ·Clinical Genitourinary Cancer ·Steven N. Seyedin, Guilherme Harada, (unknown), (unknown), (unknown), (unknown), Arash Rezazadeh Kalebasty, Mitra Daneshvar, Nataliya Mar	1
5	Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function 2023 ·Journal of Thoracic Oncology ·Monica F. Chen, Guilherme Harada, Dazhi Liu, (unknown), Christina J. Falcon, Clare Wilhelm, Mark G. Kris, Alexander Drilon, Victoria Gutgarts	11
6	Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers 2023 ·Clinical Cancer Research ·Julia Rotow, Jyoti D. Patel, (unknown), Helena A. Yu, Mark M. Awad, Jonathan W. Goldman, Hovav Nechushtan, Matthias Scheffler, Chih‐Hsi S. Kuo, Senthil Rajappa, Guilherme Harada, (unknown), (unknown), (unknown), Rebecca Tupper, Geoffrey R. Oxnard, Jennifer Kherani, Alexander Drilon	26
7	Rare molecular subtypes of lung cancer 2023 ·Nature Reviews Clinical Oncology ·Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, Alexander Drilon	57
8	Cushing’s syndrome due to ectopic adrenocorticotropin secretion by a parotid carcinoma 2022 ·Archives of Endocrinology and Metabolism ·(unknown), Guilherme Harada, (unknown), (unknown), (unknown), Luiz Paulo Kowalski, Madson Q. Almeida, Gilberto de Castro	0
9	Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy 2022 ·Journal of Thoracic Oncology ·Or Kalchiem‐Dekel, Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, (unknown), Clare Wilhelm, (unknown), Guilherme Harada, Lori J. Wirth, Subba R. Digumarthy, Robert P. Lee, (unknown), Robin B. Mendelsohn, Jessica Donington, Justin F. Gainor, Alexander Drilon, W. Marston Linehan	29
10	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis 2022 ·Translational Oncology ·(unknown), (unknown), Guilherme Harada, (unknown), Artur Katz, Denis L. Jardim	10
11	Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors 2022 ·Investigational New Drugs ·Emiliano Calvo, Cristiana Sessa, Guilherme Harada, Maria J. de Miguel, Carmen Kahatt, (unknown), Mariano Siguero, Carlos Fernández‐Teruel, Martín Cullell-Young, Anastasios Stathis, Alexander Drilon	6
12	Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Guilherme Harada, (unknown), (unknown), (unknown), Marcelo A. Queiroz, (unknown), Fábio de Oliveira Ferreira, Rodrigo Ramella Munhoz	0
13	Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer 2021 ·Jornal Brasileiro de Pneumologia ·Guilherme Harada, (unknown), Renata Colombo Bonadio, (unknown), Rafael Caparica, (unknown), Teresa Yae Takagaki, Felipe Roitberg, Ricardo Mingarini Terra, Gilberto de Castro	8
14	Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report 2021 ·Clinical Lung Cancer ·Guilherme Harada, Mariane Tami Amano, (unknown), (unknown), (unknown), Carlos Alberto Buchpiguel, Gilberto de Castro	0
15	COVID-19 in a Patient with Advanced Merkel Cell Carcinoma Receiving Immunotherapy 2020 ·Immunotherapy ·(unknown), (unknown), (unknown), Guilherme Harada, (unknown), (unknown), Artur Katz, Rodrigo Ramella Munhoz	6
16	Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project) 2020 ·ESMO Open ·Martín Ángel, Renata Colombo Bonadio, Guilherme Harada, (unknown), Diego Enrico, Óscar Arrieta, Luis Corrales, Claudio Martín, Gustavo Werutsky, Carlos H. Barrios, Luisa Ricaurte, Andrés F. Cardona	7
17	TRK Inhibitors in Non-Small Cell Lung Cancer 2020 ·Current Treatment Options in Oncology ·Guilherme Harada, (unknown), (unknown), Fernando C. Santini	13
18	U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer 2019 ·International Journal of Technology Assessment in Health Care ·(unknown), (unknown), (unknown), Guilherme Harada, Moacyr Roberto Cucê Nobre	17
19	Induction Chemotherapy for Locally Advanced Esophageal Cancer 2019 ·Journal of Gastrointestinal Cancer ·Guilherme Harada, (unknown), (unknown), (unknown), Rubens Antônio Aissar Sallum, Ulysses Ribeiro, Ivan Cecconello, Flávio Roberto Takeda, Tiago Biachi De Castria	11
20	Early stage primary gastric diffuse large B-cell lymphoma in a young HIV-positive patient 2014 ·Autopsy and Case Reports ·Guilherme Harada, Aloísio Felipe-Silva, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact